BlossomHill insider converts 578K preferred
Rhea-AI Filing Summary
BlossomHill Therapeutics, Inc. (BLSM) reported that on August 10, 2026, 578,524 shares of Series B Preferred Stock held indirectly through Brahma BlossomHill Partners, LLC automatically converted into 578,524 shares of Common Stock upon the closing of BlossomHill Therapeutics’ initial public offering, with the preferred shares then reduced to zero. These securities are held of record by Brahma BlossomHill Partners, LLC, which is managed by an entity founded and led by director Sundeep Agrawal; he may be deemed to have voting or investment power but expressly disclaims beneficial ownership.
Separately, on August 6, 2026, Agrawal received a director stock option to purchase 23,904 shares of Common Stock at an exercise price of $16.00 per share, expiring on August 5, 2036. According to the vesting terms, 1/36 of the option shares vest in equal monthly installments over three years following August 6, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
578,524 shares exercised/converted
Exercise
3 txns
Insider
Agrawal Sundeep
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock F1, F2 | 578,524 | -- | -- |
| Conversion | Common Stock F1, F2 | 578,524 | -- | -- |
| Grant/Award | Director Stock Option (Right to Buy) F3 | 23,904 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 23,904 contracts (Direct);
Series B Preferred Stock — 0 contracts (Indirect, By Brahma BlossomHill Partners, LLC);
Common Stock — 578,524 shares (Indirect, By Brahma BlossomHill Partners, LLC)
Footnotes (3)
- F1. Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
- F2. The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- F3. 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
Key Figures
Series B Preferred Stock converted: 578,524 shares
Common Stock received on conversion: 578,524 shares
Director Stock Option grant size: 23,904 shares
+3 more
6 metrics
Series B Preferred Stock converted
578,524 shares
Automatically converted into Common Stock on August 10, 2026 upon IPO closing
Common Stock received on conversion
578,524 shares
Indirectly held by Brahma BlossomHill Partners, LLC after conversion
Director Stock Option grant size
23,904 shares
Option to buy Common Stock granted August 6, 2026
Director Stock Option exercise price
$16.00 per share
Exercise price for 23,904-share option grant
Option expiration date
August 5, 2036
Expiration for director stock option on 23,904 shares
Option vesting rate
1/36 per month
Vests in equal monthly installments over three years after August 6, 2026
Key Terms
Series B Preferred Stock, initial public offering, beneficial ownership, Director Stock Option, +1 more
5 terms
Series B Preferred Stock financial
"Each share of Series B Preferred Stock automatically converted into 1 share"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
initial public offering financial
"automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Director Stock Option financial
"Director Stock Option (Right to Buy)"
vesting financial
"1/36th of the shares subject to the option shall vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
Who is the reporting insider in BlossomHill Therapeutics (BLSM) Form 4?
The reporting person is Sundeep Agrawal, a director of BlossomHill Therapeutics. The securities are held of record by Brahma BlossomHill Partners, LLC; Agrawal may be deemed to have voting or investment power but disclaims beneficial ownership of these securities.
What stock option grant did director Sundeep Agrawal receive from BLSM?
On August 6, 2026, Sundeep Agrawal received a director stock option for 23,904 shares of Common Stock with an exercise price of $16.00 per share, expiring on August 5, 2036, subject to vesting conditions.
What are the vesting terms of the BLSM director stock option reported?
The Form 4 states that 1/36 of the shares subject to the option vest in equal monthly installments over a three-year period following August 6, 2026, resulting in gradual vesting of the 23,904 underlying Common Stock shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
